Methadone toxicity due to smoking cessation-a case report on the drug-drug interaction involving cytochrome p450 isoenzyme 1a2

Annals of Pharmacotherapy

Volumn 45, Issue 6, 2011, Pages 34-

  Wahawisan, Joy ^a   Kolluru, Srikanth ^a   Nguyen, Tu ^a   Molina, Christina ^b   Speake, Joseph ^c  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Cyp1a2 metabolism; Methadone; Nicotine; Smoking cessation

Indexed keywords

ACETYLSALICYLIC ACID; CIGARETTE SMOKE; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 1A2; ETIRACETAM; FENTANYL; LISINOPRIL; METHADONE; NALOXONE; POLYCYCLIC AROMATIC HYDROCARBON; SIMVASTATIN; TOBACCO SMOKE; TOPIRAMATE;

ADULT; ARTICLE; BACKACHE; BLOOD GAS ANALYSIS; BREATHING RATE; CASE REPORT; CHRONIC PAIN; CIGARETTE SMOKING; DRUG INTERACTION; DRUG METABOLISM; DRUG TOXICITY; DYSPNEA; ELECTROCARDIOGRAM; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; LETHARGY; MALE; MENTAL HEALTH; NICOTINE REPLACEMENT THERAPY; PAIN; PRIORITY JOURNAL; PULSE OXIMETRY; RESPIRATORY ACIDOSIS; SINUS RHYTHM; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE;

ANALGESICS, OPIOID; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MALE; METHADONE; MIDDLE AGED; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 79958848349     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P759     Document Type: Article

References (15)

1. Tredger JM, Stoll S. Cytochromes P450-their impact on drug treatment. Hosp Pharm 2002;9:167-73.
2. Product information. Dolophine (methadone). Columbus, OH: Roxane Laboratories, Inc., November 2006.
3. Shiran MR, Lennard MS, Iqbal MZ, et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 2009;67:29-37.
4. Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 2004;50:551-9.
5. Clark JD. Understanding methadone metabolism: a foundation for safer use. Anesthesiology 2008;108:351-2.
6. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 2008;121:66-71.
7. Richter KP, Hamilton AK, Hall S, Catley D, Cox LS, Grobe J. Patterns of smoking and methadone dose in drug treatment patients. Exp Clin Psychopharmacol 2007;15:144-153. DOI 10.1037/1064-1297.15.2.144
8. Frosch DL, Shoptaw S, Nahom D, Jarvik ME. Associations between tobacco smoking and illicit drug use among methadone-maintained opiatedependent individuals. Exp Clin Psychopharmacol 2000;8:97-103. DOI 10.1037/1064-1297.8.1.97
9. Tacke U, Wolff K, Finch E, Strang J. The effect of tobacco smoking on subjective symptoms of inadequacy ("not holding") of methadone dose among opiate addicts in methadone maintenance treatment. Addict Biol 2001;6:137-45. DOI 10.1080/ 135562100 20040217
10. Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000;356:2069-70. DOI 10.1016/S0140-6736(00)03409-7
11. Mitchell TB, Dyer KR, Newcombe D, Somogyl AA, White JM. Fluctuations in (R,S)-methadone pharmacokinetics and response among longterm methadone maintenance patients. Addict Biol 2006;11:170-4. DOI 10.1111/j.1369-1600.2006.00014.x
12. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 2007;321:389-99. DOI 10.1124/jpet.106.117580
13. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999;36:425-38.
14. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004;76:178-84. DOI 10.1016/j.clpt.2004.04.003
15. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80. DOI 10.1345/aph.1H423